SCHEMBL3107538

SCHEMBL3107538

Cc1[c]cc(-c2ccc(Cl)cc2C)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.45
ESR1 P03372 1/20 0.37
CASP3 P42574 2/20 0.34
CYP3A4 P08684 2/20 0.33
MAPKAPK2 P49137 1/20 0.33
KDM4E B2RXH2 4/20 0.33
POLB P06746 3/20 0.33
NPSR1 Q6W5P4 3/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
LMNA P02545 2/20 0.32
S1PR2 O95136 1/20 0.32
S1PR4 O95977 1/20 0.32
HTT P42858 1/20 0.32
S1PR3 Q99500 1/20 0.32
S1PR5 Q9H228 1/20 0.32
ALDH1A1 P00352 4/20 0.32
TAAR1 Q96RJ0 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328314 0.74 NPC1 (0.41) NOTUMKDM4EPOLBNPSR1NPC1
SCHEMBL29719717 0.72 NOTUM (0.53) NOTUMCASP3CYP3A4POLBHSD11B1
SCHEMBL12071484 0.68 NOTUM (0.50) NOTUMCASP3CYP3A4POLBLMNA
SCHEMBL31692083 0.68 NOTUM (0.41) NOTUMESR1CASP3MAPKAPK2KDM4E
SCHEMBL19683347 0.68 NOTUM (0.41) NOTUMESR1CASP3MAPKAPK2KDM4E
SCHEMBL18856572 0.68 ESR1 (0.43) NOTUMESR1CASP3CYP3A4MAPKAPK2
SCHEMBL3030714 0.67 ALDH1A1 (0.50) NOTUMESR1CYP3A4KDM4EPOLB
SCHEMBL12497363 0.66 NOTUM (0.48) NOTUMESR1CYP3A4HSD11B1CYP1A2
SCHEMBL3102519 0.66 NOTUM (0.42) NOTUMESR1MAPKAPK2KDM4EPOLB
SCHEMBL3094113 0.66 NOTUM (0.39) NOTUMESR1MAPKAPK2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR NOTUM 2196/4885ESR1 606/4885CASP3 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.